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MaOBJECTIVES This study aimed to investigate the clinical outcomes of patients presenting with recurrent drug-eluting
stent (DES) in-stent restenosis (ISR) treated with a second-generation DES or with a drug-coated balloon (DCB).
BACKGROUND To date, there are no reports of DCB treatment and limited data with regard to the efﬁcacy of further
DES implantation for recurrent ISR.
METHODS Between January 2008 and December 2013, 171 lesions were assessed for eligibility (82 lesions in the
second-generation DES group and 89 lesions in the DCB group).
RESULTS Acute gain was greater in the second-generation DES group (second-generation DES, 2.09  0.53 mm vs.
DCBs, 1.60  0.62 mm, p < 0.001). The rates of major adverse cardiac events were comparable (at 1 year, DES 14.0% vs.
DCBs 12.3%; at 2 years, DES 28.8% vs. DCBs 43.5%, p ¼ 0.21). Major adverse cardiac event rates were mainly driven by
target lesion revascularization (at 1 year, DES 12.5% vs. DCBs 10.9%; at 2 years, DES 27.7% vs. DCBs 38.3%; p ¼ 0.40).
Deﬁnite scaffold thrombosis occurred in 2 patients (1 patient in each group). Multivariable analysis revealed ISR recur-
rence within 1 year (hazard ratio: 2.43, 95% conﬁdence interval: 1.14 to 5.18, p ¼ 0.02) and lesion length (per 10-mm
increase) (hazard ratio: 1.15, 95% conﬁdence interval: 1.00 to 1.32, p ¼ 0.049) to be independent predictors of TLR.
CONCLUSIONS The results after both treatments were equivalent. ISR recurrence within 1 year of the ﬁrst reinter-
vention and lesion length were independent predictors of future target lesion revascularization. Larger studies are
required to conﬁrm the late (>1 year) differences with regard to clinical outcomes. (J AmColl Cardiol Intv 2015;8:1586–94)
© 2015 by the American College of Cardiology Foundation.P ercutaneous coronary intervention (PCI) withdrug-eluting stents (DES) has dramaticallyreduced the rate of in-stent restenosis (ISR)
(1), and clinical outcomes have further improved with
the advent of second-generation DES. However, the
widespread use of second-generation DES has resulted
in a large number of patients (in absolute terms)
presenting with DES failure (2). The optimal manage-
ment for DES-ISR lesions is not currently established.
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quirement for prolonged dual antiplatelet therapy
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AB BR E V I A T I O N S
AND ACRONYM S
BMS = bare-metal stent(s)
CI = conﬁdence interval
DAPT = dual antiplatelet
therapy
DCB = drug-coated balloon
DES = drug-eluting stent(s)
HR = hazard ratio
ISR = in-stent restenosis
IVUS = intravascular
ultrasound
MACE = major adverse cardiac
event(s)
PCI = percutaneous coronary
intervention
ST = stent thrombosis
TLR = target lesion
revascularization
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1587The drug-coated balloon (DCB) is an attractive op-
tion in the management of this patient group. DCB
use avoids an additional metal layer at the site of ISR,
which may reduce the risk of future ST or bleeding
due to the requirement for shorter DAPT compared
with DES. DCBs have already been associated with
more favorable outcomes compared with conven-
tional balloon angioplasty (12–14) in the treatment of
bare-metal stent (BMS) or DES ISR. However, the use
of a DCB to treat recurrent multilayered-metal ISR has
not been reported.
The aim of this study was to investigate the efﬁ-
cacy, safety, and clinical outcomes associated with
DCB use for the treatment of recurrent DES-ISR with
multimetal layers compared with additional DES
implantation.
METHODS
STUDY POPULATION. We analyzed all PCI procedures
between January 2008 and December 2013 at 2 cen-
ters (San Raffaele Scientiﬁc Institute and EMO-GVM
Centro Cuore Columbus, Milan, Italy). A total ofFIGURE 1 Chart Demonstrating the Study Design and Inclusion Crite
Between January 2008 and December 2013, 171 lesions were assessed
89 lesions in the DCB group). BMS ¼ bare-metal stent(s); DCB ¼ drug-c
PCI ¼ percutaneous coronary intervention.746 lesions were treated with DES implan-
tation for BMS- or DES-ISR during the study
period. Of these, 179 lesions were recurrent
ISR lesions and were treated by DCB and/or
second-generation DES implantation. The
patient ﬂow is illustrated in Figure 1. Of the
total 179 lesions, we excluded 8 lesions that
were treated with both a DCB and DES;
therefore, we analyzed 171 lesions (82 lesions
[n ¼ 68] in the second-generation DES group,
and 89 lesions [n ¼ 65] in the DCB group).
Each patient provided written informed
consent for data collection and analysis, ac-
cording to the Declaration of Helsinki. All
clinical follow-up was conducted via hospital
visits or telephone consultations.
STUDY DEVICES. The second-generation DES
in this study included everolimus-eluting
stents (Xience V, Xience Prime, Abbott
Vascular, Santa Clara, California; PROMUS
and PROMUS ELEMENT, Boston Scientiﬁc Corp.,
Natick, Massachusetts), zotarolimus-eluting stent
(Endeavor Resolute, Medtronic Vascular, Santa Rosa,ria
for eligibility (82 lesions in the second-generation DES group, and
oated balloon; DES ¼ drug-eluting stent(s); ISR ¼ in-stent restenosis;
TABLE 1 Patient Demographic, Lesion, and Procedural Characteristics
Second-Generation
DES DCBs p Value
Patient characteristics
No. of patients 68 65
No. of lesions 82 89
Male, n (%) 63 (92.6) 57 (87.7) 0.34
Age, yrs 64.9  9.1 67.2  8.9 0.16
DM 28 (41.2) 28 (43.1) 0.82
Insulin-dependent DM 6 (8.8) 9 (13.8) 0.36
Current smoking 9 (13.2) 6 (9.2) 0.47
Family history of CAD 36 (52.9) 33 (50.8) 0.80
Hypertension 54 (79.4) 51 (78.5) 0.89
Dyslipidemia 54 (79.4) 51 (78.5) 0.89
Previous CABG 27 (39.7) 17 (26.2) 0.10
Previous MI 42 (61.8) 36 (55.4) 0.46
CKD, eGFR <60 ml/min/1.73 m2 39 (58.2) 40 (61.5) 0.70
Ejection fraction, % 52.0  9.0 53.1  8.8 0.51
Acute coronary syndrome 10 (14.7) 12 (18.5) 0.56
No. of diseased vessels 0.43
1 13 (19.1) 14 (21.5)
2 26 (38.2) 18 (27.7)
3 29 (42.6) 33 (50.8)
Lesion and procedure characteristics
Days from 1st to 2nd PCI 1,034  1,050 1,139  1,197 0.55
Days from 2nd to 3rd PCI 1,037  810 1,414  1,015 0.01
Target vessel 0.07
Left main trunk 3 (3.7) 2 (2.2)
Left anterior descending artery 24 (29.3) 39 (43.8)
Left circumﬂex artery 17 (20.7) 18 (20.2)
Right coronary artery 23 (28.0) 25 (28.1)
Saphenous venous graft 15 (18.3) 5 (5.6)
1st PCI
Stent type 0.19
BMS 25 (30.5) 26 (29.2)
DES 52 (63.4) 62 (69.7)
Unknown 5 (6.1) 1 (1.1)
Type of DES 0.01
Sirolimus-eluting stent 21 (40.4) 29 (46.8)
Paclitaxel-eluting stent 15 (28.8) 15 (24.2)
Zotarolimus-eluting stent 2 (3.8) 4 (6.5)
Biolimus-eluting stent 0 1 (1.6)
Everolimus-eluting stent 12 (23.1) 2 (3.2)
Unknown DES 2 (3.8) 11 (17.7)
Stent size, mm 3.13  0.37 2.99  0.56 0.12
Stent length, mm 21.3  8.0 24.2  9.8 0.10
Continued on the next page
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1588California), Nobori biolimus A9–eluting stents
(Terumo Corporation, Tokyo, Japan), Biomatrix (Bio-
sensors International, Singapore), and amphilimus-
eluting stent (Cre8 BTK, Alvimedica/CID. S.p.A.,
Saluggia, Italy). The DCBs used in this study included
the In.Pact Falcon (Medtronic Vascular) and Pantera
Lux (Biotronik, Berlin, Germany).
PROCEDURE. Standard procedures were used for
PCI for recurrent ISR. In particular, adequate lesion
preparation with the use of conventional balloons(semicompliant or noncompliant) was considered
mandatory before either DES or DCB use. High-
pressure post-dilation with noncompliant balloons
was recommended after DES implantation. In the
DCB group, if acceptable angiographic results after pre-
dilation were obtained (15), the DCB was inﬂated at a
nominal pressure for a minimum of 30 to 60 seconds to
aid drug delivery to the vessel wall. In both groups, the
use of intravascular ultrasound (IVUS) was left to the
operators’ discretion.
Lifelong low-dose aspirin use was recommended
for all patients in addition to a thienopyridine (200 to
250 mg ticlopidine twice daily or 75 mg clopidogrel
daily) for a minimum of 12 months after DES im-
plantation or 1 month after angioplasty with a DCB. In
cases of ISR within 1 year after DES implantation, the
duration of DAPT in the DCB group depended on the
date of the previous DES implantation. Unfraction-
ated heparin was administered at a dose of 70 to 100
U/kg for all patients. If required, glycoprotein IIb/IIIa
inhibitors were used at the operators’ discretion.
STUDY DEFINITIONS. Recurrent ISR was deﬁned as
restenosis after a PCI for a restenotic stent lesion
treated with a DES at the time of the last procedure
(Figure 1). The ﬁrst PCI was deﬁned as the index PCI
with BMS or DES implantation (in which ISR later
developed). The second PCI was deﬁned as DES
implantation for an ISR lesion. The third PCI, the
procedure evaluated in this study, was deﬁned as
second-generation DES implantation or balloon an-
gioplasty with a DCB for a recurrent ISR lesion after
the second PCI. Major adverse cardiac events (MACE)
were deﬁned as the composite endpoint of all-cause
death, myocardial infarction, and target lesion
revascularization (TLR). Death was considered car-
diac in origin unless unequivocal noncardiac causes
were identiﬁed. We deﬁned periprocedural myocar-
dial infarction as an increase of creatine kinase-
myocardial band level to more than 3 times the limit
of normal (16). Creatine kinase was routinely
measured after PCI in all patients at both centers.
Nonprocedural myocardial infarction was deﬁned as
an elevation of cardiac biomarker values (preferably
cardiac troponin) above the upper range limit in
combination with at least 1 of the following: ischemic
symptoms, electrocardiographic changes indicative
of new ischemia, development of new pathological Q
waves on the electrocardiogram, imaging evidence
of a new loss of viable myocardium or new regional
wall motion abnormality, or identiﬁcation of an
intracoronary thrombus by angiography or autopsy
(17). TLR was deﬁned as repeat PCI or coronary artery
bypass grafting for the lesion in the previously
TABLE 1 Continued
Second-Generation
DES DCBs p Value
2nd PCI
Type of DES 0.90
Sirolimus-eluting stent 21 (25.6) 20 (22.5)
Paclitaxel-eluting stent 24 (29.3) 21 (23.6)
Zotarolimus-eluting stent 11 (13.4) 14 (15.7)
Biolimus-eluting stent 4 (4.9) 4 (4.5)
Everolimus-eluting stent 19 (23.2) 25 (28.1)
Unknown DES 3 (3.7) 5 (5.6)
Stent size, mm 3.13  0.40 3.13  0.45 0.96
Stent length, mm 24.1  8.1 21.8  7.7 0.08
3rd PCI
ISR pattern, n (%) 0.005
Focal lesion 49 (59.8) 34 (38.2)
IA/IB/IC/ID 2 (2.4)/9 (11.0)/32
(39.0)/6 (7.3)
1 (1.1)/5 (5.6)/24
(27.0)/4 (4.5)
Nonfocal lesion 33 (40.2) 55 (61.8)
II/III/IV 21 (25.6)/2
(2.4)/10 (12.2)
45 (50.6)/9
(10.1)/1 (1.1)
Type B2/C 57 (69.5) 68 (76.4) 0.31
Ostial lesion 14 (17.1) 14 (15.7) 0.81
Bifurcation lesion 11 (13.4) 17 (19.1) 0.32
IVUS 11 (13.4) 30 (33.7) 0.002
Pre-dilation 60 (81.1) 50 (61.0) 0.006
Type of DES
Zotarolimus-eluting stent 14 (17.0)
Biolimus-eluting stent 18 (22.0)
Everolimus-eluting stent 45 (54.9)
Amphilimus-eluting stent 5 (6.1)
Stent size, mm 3.20  0.40
Stent length, mm 25.0  17.2
Post-dilation 49 (66.2)
Type of DCB
In.Pact Falcon (Medtronic Vascular) 87 (97.8)
Pantera Lux (Biotronik) 2 (2.2)
Balloon size, mm 3.14  0.39
Balloon length, mm 33.7  7.9
Maximal balloon pressure, atm 11.5  4.1
Different drug 72 (87.8) 68 (76.4) 0.05
Values are n (%) and mean  SD.
DES ¼ drug-eluting stent; DCBs ¼ drug-coated balloon; DM ¼ diabetes mellitus; CAD ¼ coronary artery
disease; CABG ¼ coronary artery bypass graft; MI ¼ myocardial infarction; CKD ¼ chronic kidney disease; eGFR ¼
estimated glomerular ﬁltration rate; PCI ¼ percutaneous coronary intervention; BMS ¼ bare-metal stent; ISR ¼
in-stent restenosis; IVUS ¼ intravascular ultrasound.
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1589stented segment or in the adjacent 5 mm. ST was
classiﬁed according to the Academic Research Con-
sortium deﬁnition and cumulative ST as a combina-
tion of all episodes of ST during follow-up (18).
Quantitative coronary angiographic analyses were
performed using matched orthogonal views before
and after each procedure. Angiographic measure-
ments were obtained after intracoronary nitrate in-
jection. Reference vessel diameter, minimal lumen
diameter, lesion length, and percentage diameter
stenosis were analyzed by an experienced cardiolo-
gist blinded to the clinical procedure and outcomes
using the Clinical Measurements Solutions system
(version 5.2, Medis Medical Imaging Systems BV,
Leiden, the Netherlands).
ENDPOINTS. The primary endpoint was the occur-
rence of MACE at 1- and 2-year follow-up. The sec-
ondary endpoints were the incidence of each
component of MACE and ST.
STATISTICAL ANALYSIS. Continuous variables are
presented as the mean  SD or median  inter-
quartile range (25th to 75th percentiles) for Gaussian
and non-Gaussian distributed variables, respectively.
Normality of each continuous variable was tested
with the Kolmogorov-Smirnov test. Differences in
continuous variables between groups were compared
using the Student t test or Mann-Whitney U test.
Categorical variables are presented as numerical
values and percentages. Categorical data were
compared using the chi-square or Fisher exact test.
The cumulative incidence of clinical events was
estimated on a per-patient basis using the Kaplan-
Meier method, and the signiﬁcance of differences
was assessed with the log-rank test. All reported p
values are 2 sided, and p values <0.05 were regarded
as statistically signiﬁcant. Multivariable Cox regres-
sion analysis was performed to identify the inde-
pendent risk factors for TLR. Variables entered into
multivariable model were those that reached signif-
icance (p < 0.10) after univariable analysis and
judged to be of clinical signiﬁcance. To avoid over-
ﬁtting, the number of independent variables entered
into the ﬁnal Cox regression model was limited to 1
for every 8 to 10 events. In the lesion-based analysis,
because observations recorded in the same patient
cannot be considered independent, the sandwich
estimator of the variance-covariance matrix was
used to take into account clustered data (more le-
sions in the same subject) (19,20). The results are
reported as hazard ratio (HR) and 95% conﬁdence
interval (CI). Analyses were performed with SPSS
version 20.0 (SPSS Inc., Chicago, Illinois) and STATA
9.0 (StataCorp, College Station, Texas).RESULTS
BASELINE CHARACTERISTICS. There were no sig-
niﬁcant differences in the baseline clinical charac-
teristics between groups, as illustrated in Table 1. The
lesion and procedural characteristics in both groups
were also comparable. The period from second PCI to
third PCI was signiﬁcantly longer in the DCB group
than in the second-generation DES group (second-
generation DES: 1,037  810 days vs. DCB group: 1,414
TABLE 2 Serial Quantitative Coronary Angiographic Results
Second-Generation
DES DCBs p Value
No. of patients 68 65
No. of lesions 82 89
Angiographic follow-up 40 (48.8) 48 (53.9) 0.50
Pre-procedural results
Reference vessel diameter, mm 2.92  0.54 2.84  0.46 0.34
Minimal lumen diameter, mm 0.66  0.43 0.74  0.49 0.24
Stenosis, % of lumen diameter 81.2  14.4 74.8  15.8 0.004
Lesion length, mm 16.1  9.6 18.7  14.6 0.18
Post-procedural results
Minimal lumen diameter, mm 2.65  0.48 2.34  0.54 <0.001
Stenosis, % of lumen diameter 13.8  7.6 18.2  8.6 <0.001
Acute gain, mm 2.09  0.53 1.60  0.62 <0.001
Values are n (%) and mean  SD.
Abbreviations as in Table 1.
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1590 1,015 days, p ¼ 0.01). Even though the types of DES
at the ﬁrst PCI were signiﬁcantly different, those of
the second PCI were comparable between groups. At
the third PCI, the patterns of ISR treated were
signiﬁcantly different between groups (second-
generation DES vs. DCBs: focal ISR [59.8% vs. 37.8%],
and nonfocal ISR [40.2% vs. 61.8%], p ¼ 0.005,
respectively). IVUS was used more frequently in the
DCB group (second-generation DES, 13.4% vs. DCBs,
33.7%, p ¼ 0.002). Pre-dilation was performed moreTABLE 3 Estimated Incidence (Kaplan-Meier Method) of
Outcomes at 1 and 2 Years
Second-Generation
DES DCBs p Value
No. of patients 68 65
No. of lesions 82 89
MACE 0.21
At 1 yr 9 (14.0) 7 (12.3)
At 2 yrs 17 (28.8) 19 (43.5)
All-cause death 0.88
At 1 yr 1 (1.6) 1 (1.6)
At 2 yrs 2 (3.3) 2 (3.6)
Myocardial infarction 0.19
At 1 yr 0 (0) 1 (1.8)
At 2 yrs 1 (1.8) 3 (7.6)
Target lesion revascularization 0.40
At 1 yr 8 (12.5) 6 (10.9)
At 2 yrs 16 (27.7) 16 (38.3)
Stent thrombosis 0.83
At 1 yr 0 (0) 0 (0)
At 2 yrs 1 (1.8) 1 (2.9)
Values are n (%) as estimated by the Kaplan-Meier method.
MACE ¼ major adverse cardiac events; other abbreviations as in Table 1.frequently in the second-generation DES group
(second-generation DES, 81.1% vs. DCBs, 61.0%, p ¼
0.006), and post-dilation was only carried out in pa-
tients treated with DES and was performed in 66.2%
of the second-generation DES group. The decision to
switch drug between the second DES and the third
PCI was more frequent in the second-generation DES
group (second-generation DES, 87.8% vs. DCBs,
76.4%, p ¼ 0.05), which was expected due to the
commercially available DCBs during the study period
being limited to paclitaxel alone. The interaction test
for treatment group (second-generation DES or DCBs)
by each center yielded a p value of 0.21 for MACE and
0.24 for TLR at 2 years.
QUANTITATIVE CORONARY ANGIOGRAPHIC ANALYSIS.
Serial angiographic results are shown in Table 2.
Pre-procedural percentage diameter stenosis was
more severe in the second-generation DES group
(second-generation DES, 81.2  14.4% vs. DCBs,
74.8  15.8%, p ¼ 0.004). However, the post-
procedural results were signiﬁcantly better in the
second-generation DES group (minimal lumen diam-
eter, 2.65  0.48 mm vs. 2.34  0.54 mm, p < 0.001;
percentage diameter stenosis, 13.8  7.6% vs. 18.2 
8.6%, p < 0.001; and acute gain, 2.09  0.53 mm vs.
1.60  0.62, p < 0.001, second-generation DES vs.
DCBs, respectively).
CLINICAL OUTCOMES. Clinical follow-up was ob-
tained for all patients. The median follow-up period
was 760 (interquartile range [IQR]: 401 to 1,150) days.
The clinical outcomes at 1- and 2-year follow-up are
shown in Table 3. MACE rates at 1 year were compara-
ble between groups (DES, 14.0% vs. DCBs, 12.3%).
MACE rates were mainly driven by TLR in both groups
(second-generation DES, 12.5% vs. DCBs, 10.9%).
Although there were no signiﬁcant differences be-
tween the 2 groups, there were trends in the clinical
outcomes that appeared to be more favorable in the
second-generation DES group with regard to both
MACE (second-generation DES, 28.8% vs. DCBs,
43.5%, p ¼ 0.21) and TLR (second-generation DES,
27.7% vs. DCBs, 38.3%; p ¼ 0.40), as shown in
Figures 2A and 2B. When patients were divided into 2
groups on the basis of the pattern of restenosis (focal
ISR group and nonfocal ISR group), lesions with non-
focal ISR treated with a DCB had a numerically higher
TLR rate compared with diffuse ISR lesions treated
with DES (second-generation DES, 27.6% vs. DCBs,
40.8%, p ¼ 0.25) (Figures 2C and 2D). In our study,
deﬁnite ST during 2 years of follow-up occurred in 2
patients (1 patient in each group), with no statistically
signiﬁcant differences between the 2 groups (second-
generation DES, 1.8% vs. DCBs, 2.9%; p ¼ 0.83).
FIGURE 2 Rates of Outcomes Among Study Patients
Kaplan-Meier curves are shown for overall major adverse cardiac events (MACE) (A), target lesion revascularization (TLR) in the overall cohort
(B), TLR in focal ISR group (C), and TLR in the nonfocal ISR group (D). Event rates are Kaplan-Meier estimates with log-rank p values.
MI ¼ myocardial infarction; other abbreviations as in Figure 1.
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1591PREDICTORS OF TLR. Univariable analysis revealed
the following risk factors for TLR: ISR recurrence
within 1 year (HR: 2.02, 95% CI: 1.02 to 3.98, p ¼
0.04) and lesion length (per 10-mm increase) (HR:
1.21, 95% CI: 1.07 to 1.37, p ¼ 0.002). The covariatesentered into the ﬁnal Cox regression model included
the period between ISR recurrence within 1 year,
diffuse ISR, the same drug between the second
and the third PCIs, IVUS-guided PCI, and lesion
length (per 10-mm increase). Multivariable analysis
TABLE 4 Univariable
Covaria
DCB
ISR recurrence within 1
ISR recurrence within 1
Ostial disease
Focal restenosis
Diffuse restenosis
Chronic total occlusion
Chronic kidney disease
(eGFR <60 ml/min
Hemodialysis
Ejection fraction
Stable angina
Same drug (2nd and 3r
IVUS-guided PCI
Type B2/C (ACC/AHA c
Bifurcation lesion
Hypertension
Dyslipidemia
Current smoking
Diabetes mellitus
Insulin-dependent diab
Lesion length (per 10-m
Diameter stenosis (per
Post-procedural minim
ACC/AHA ¼ American Colle
ratio; IVUS ¼ intravascular
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1592revealed ISR recurrence within 1 year (HR: 2.43, 95%
CI: 1.14 to 5.18, p ¼ 0.02) and lesion length (per
10-mm increase) (HR: 1.15, 95% CI: 1.00 to 1.32,
p ¼ 0.049) to be independent predictors of TLR
(Table 4).DISCUSSION
This study is the ﬁrst comparison between second-
generation DES and DCBs for the treatment of
recurrent multimetal-layered ISR. The main ﬁndings
of our study are the following: 1) acute gain was
greater in the second-generation DES group; 2) the
results after both treatments were equivalent during
the deﬁned follow-up period; 3) early recurrence
(within 1 year) of ISR after the ﬁrst reintervention
and lesion length were independent predictors of
future TLR.
Several randomized and observational studies re-
ported clinical outcomes after treatment of ISR
(2,7,14,21,22). However, there are only limited data
regarding outcomes after treatment of recurrent ISR.
Although DCBs have been considered an alternativeand Multivariable Analysis of Target Lesion Revascularization
tes
Univariable Multivariable
HR (95% CI) p Value HR (95% CI) p Value
1.26 (0.71–2.24) 0.43
80 days 1.93 (0.47–7.96) 0.36
yr 2.02 (1.02–3.98) 0.04 2.43 (1.14–5.18) 0.02
1.13 (0.56–2.27) 0.73
1.01 (0.58–1.77) 0.97
1.23 (0.70–2.17) 0.46 1.21 (0.64–2.27) 0.56
3.90 (0.54–28.27) 0.18
/1.73 m2)
1.19 (0.67–2.12) 0.55
2.45 (0.59–10.22) 0.22
1.00 (0.97–1.03) 0.99
1.29 (0.63–2.67) 0.49
d PCIs) 0.54 (0.21–1.36) 0.19 0.51 (0.18–1.39) 0.19
0.59 (0.29–1.21) 0.15 0.59 (0.28–1.23) 0.16
lassiﬁcation) 1.01 (0.54–1.91) 0.98
1.25 (0.62–2.51) 0.53
1.07 (0.54–2.09) 0.85
1.35 (0.71–2.56) 0.36
1.54 (0.65–3.62) 0.33
1.20 (0.69–2.11) 0.52
etes mellitus 1.44 (0.68–3.08) 0.34
m increase) 1.21 (1.07–1.37) 0.002 1.15 (1.00–1.32) 0.049
10% increase) 1.04 (0.88–1.24) 0.65
al lumen diameter 1.06 (0.64–1.73) 0.83
ge of Cardiology/American Heart Association; CI ¼ conﬁdence interval; HR ¼ hazard
ultrasound.treatment option for DES-ISR (12,13,23), the effec-
tiveness of DCBs for recurrent multimetal-layered ISR
has not been investigated. Kubo et al. (11) reported
that the third metal (DES) implantation is more
effective to reduce TLR compared with conventional
balloon angioplasty. In the present study comparing
the clinical outcomes between second-generation
DES implantation and angioplasty with DCBs for
recurrent multimetal-layered ISR, we highlighted
that both therapeutic strategies are associated with
acceptable 1- and 2-year clinical outcomes. The inci-
dence of MACE or TLR in both groups was comparable
to that of previous studies (7,11,23), with the
increased MACE rate mainly attributable to TLR
(second-generation DES vs. DCBs at 1 year: 12.5% vs.
10.9% and DES vs. DCBs at 2 years: 27.7% vs. 38.3%,
p ¼ 0.40).
There are some possible confounders that may
have affected the late outcomes in this non-
randomized study. First, each clinical event may be
overestimated for the late (>1 year) outcomes because
of the small number of patients and short follow-up
period in the DCB group in particular (median
follow-up period: second-generation DES, 826 [IQR:
495 to 1,175] vs. DCBs, 613 [IQR: 365 to 1,097],
p ¼ 0.04). Second, the occurrence of nonfocal ISR
lesions was higher in the DCB group (second-
generation DES, 40.2% vs. DCBs, 61.8%) and may
have accounted for worse outcomes. Third, the acute
gain was smaller in the DCB group compared with the
second-generation DES group (second-generation
DES, 2.09  0.53 mm vs. the DCB group, 1.60 
0.62 mm, p < 0.001), with similar late lumen loss in
both groups (23). Pre-dilation was performed more
frequently in the second-generation DES group and
may be an effective strategy in cases of PCI for ISR
lesions, especially when caused by underexpanded
stents (24) (with the risk of causing ﬂow-limiting
dissection, which would necessitate bailout stent-
ing). The effects of post-dilation may also have had an
effect, with 66.2% of the DES group being treated
with post-dilation but no patients in the DCB group,
in keeping with the manufacturer’s recommendations
due to the concern of the effects on drug delivery to
the endovascular surface.
Intravascular imaging (IVUS or optical coherence
tomography) has been considered a useful adjunctive
tool when treating ISR lesions and can be used to
identify the mechanism of restenosis and for the
evaluation of plaque morphology (24,25). In our
study, IVUS was performed more frequently in the
DCB group (second-generation DES group, 13.4% vs.
DCB group, 33.7%, p ¼ 0.002). The more frequent use
of IVUS may have improved outcomes in the DCB
PERSPECTIVES
WHAT IS KNOWN? Approximately 10% to 20% of patients
with DES failure experience recurrent ISR. There are only a few
studies investigating outcomes after repeated DES treatment of
recurrent multimetal-layered ISR, and the optimal management
of these patients remains unknown. DCB use avoids an additional
metal layer at the site of ISR, which may reduce the risk of future
ST or bleeding due to the need for shorter DAPT compared with
DES.
WHAT IS NEW? This study demonstrated that clinical out-
comes were comparable when recurrent multimetal-layered ISR
was treated with either DCB or second-generation DES. Howev-
er, there were trends in the clinical outcomes that appeared to be
more favorable in the second-generation DES group with regard
to both MACE and TLR. Recurrent ISR that occurred within 1 year
of the ﬁrst reintervention and lesion length were identiﬁed as
independent predictors of future TLR.
WHAT IS NEXT? This study conﬁrms the efﬁcacy of both
treatment options. A large prospective, randomized study is
required to further investigate the role of DCB or second-
generation DES for the treatment of multimetal-layered ISR to
overcome some of the possible confounders in this retrospective
study.
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1593group (TLR, 10.9% at 1 year), and a further improve-
ment in outcomes could be expected with greater use
of IVUS in the DES group.
In the current analysis, multivariable Cox regres-
sion analysis revealed lesion length and ISR recur-
rence within 1 year to be independent predictors of
TLR. Early recurrence (within 1 year) of ISR may be a
consequence of the plaque characteristics of the
neointima (25). With regard to the early ISR cohort
(DES, 21 lesions; DCBs, 9 lesions), TLR occurred in
7 lesions (33%) in the DES group and 5 lesions (55%)
in the DCB group. A diffuse ISR pattern has been
reported as a predictor of recurrent restenosis
(11,26,27). We demonstrated that lesion length
(length of ISR with multimetal layers) was also an
independent predictor of further TLR, although a
nonfocal ISR pattern was not. These differences may
be due to the small number of patients in this study.
It should be noted that deﬁnite ST occurred in
2 cases (1 case in each group) in our study. One pa-
tient on aspirin monotherapy had ST at 560 days
after DCB treatment. The second patient on DAPT
had ST at 382 days after second-generation DES
implantation.
Bioresorbable scaffold implantation for ISR lesions
may also be an alternate strategy that would avoid
implantation of additional metal (28). However, the
current bioresorbable scaffold (e.g., Absorb revision
1.1, Abbott Vascular) does not completely resorb until
2 to 3 years post-implantation, and their bulky plat-
form (157-mm strut thickness) may preclude future
reintervention. Newer generation scaffolds that are
thinner and completely resorbed within 6 to 12
months may prove to be a more ideal treatment
option.
STUDY LIMITATIONS. The patients in this study were
not randomized. There were differences in the lesion
characteristics in each of the 2 groups such as the ISR
type; however, this did not appear to be a risk factor
for future events on the basis of the results of the
univariate Cox regression analysis. The lesion char-
acteristics at the time of the index PCI were unknown
because procedural information was not available in
all cases, and we were also unable to take into ac-
count plaque morphology or stent underexpansion,
which are important factors when evaluating out-
comes of ISR lesions due to IVUS being performed in
only one-fourth of lesions. Furthermore, we could not
show the pre-dilation pressure because of missing
values. The DCBs used in this current study were the
In.Pact Falcon (Medtronic Vascular) and the Pantera
Lux (Biotronik, Berlin, Germany); however, the
greatest experience to date in the published data hasbeen with the use of the SeQuent Please DCB (B.
Braun, Melsungen, Germany) (12,23,29), and one
cannot automatically assume similar efﬁcacy be-
tween different devices and a class effect. Finally, as
expected, for a low-frequency event, the patient
number was low, precluding propensity matching,
and we did not ﬁnd a difference between groups. A
larger prospective, randomized study is required to
conﬁrm these ﬁndings.
CONCLUSIONS
The clinical outcomes were comparable when recur-
rent multimetal-layered ISR was treated with either
DCBs or second-generation DES. ISR that recurred
within 1 year of the ﬁrst reintervention and lesion
length were identiﬁed as independent predictors of
future TLR. Larger randomized studies are required
to conﬁrm these ﬁndings.
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